CORT · Corcept Therapeutics Incorporated · Stock research

Current Thesis

The July framing was that the run had front-run its own print. The print arrived a week earlier than the placeholder date — 2026-07-29 — and it settled the question in the bulls' favour. Q2 revenue was $256.1M against a $219.99M consensus, diluted EPS $0.36 against a $(0.00) estimate, net income $43.0M versus $35.1M a year earlier, and management took FY2026 guidance to $1.1–1.2B from $950M–$1.05B while the street sat at $1.008B. Lifyorli (relacorilant + nab-paclitaxel) contributed $47.6M in its first quarter of availability with more than 1,300 patients started since the 2026-03-25 approval. Shares moved +21.95% after hours on the release and the sell-side repriced within 24 hours. What has changed since the last note is that the oncology ramp is now a reported number rather than an assumption, and the Q1 deceleration scare ($164.9M, +4.9% YoY, a $31.8M net loss) reads as launch-quarter noise. What has not changed is the shape of the calendar: the next company-specific binary is the 2026-12-17 PDUFA for relacorilant in hypercortisolism, roughly four months out, and the stock enters that gap 6.4% below a 52-week high it set after the print.

Bullish and bearish views on Corcept Therapeutics Incorporated

The model's bull view on Corcept Therapeutics Incorporated (CORT), in brief: Q2 2026 (2026-07-29) beat on both lines. The bear view: A four-month catalyst vacuum. Between the 2026-07-29 print and the 2026-12-17 PDUFA there is no company-confirmed binary. BELLA Part A, the ROSELLA EU MAA decision and the MONARCH Phase 2b MASH readout are all guided only to "end of 2026". Dispersion is extreme and one side is… Both cases follow in full.

Bull Case

• Q2 2026 (2026-07-29) beat on both lines. Revenue $256.1M, +32% YoY from $194.4M; diluted EPS $0.36 vs a $(0.00) consensus; net income $43.0M vs $35.1M in Q2 2025.
• The launch printed a real number. Lifyorli revenue $47.6M in its first quarter of availability; over 1,300 patients started treatment since the 2026-03-25 FDA approval. NCCN listed the regimen as preferred in April 2026.
• Guidance raised by more than the beat. FY2026 revenue guide lifted to $1.1–1.2B from $950M–$1.05B (2026-07-29), against a $1.008B consensus — the second raise of the year after the 2026-04-30 lift.
• The endocrine base still grows. Korlym and authorized-generic revenue $208.6M in Q2 2026 versus $194.4M in Q2 2025, so the oncology ramp is additive rather than substitutive.
• Second approval is dated. The Cushing's NDA, physically resubmitted 2026-06-17, carries a PDUFA target action date of 2026-12-17. No new trials were required; the resubmission is additional analyses of the original dataset.
• Funded through the decision. Cash and investments $544.6M at 2026-06-30, up from $515.4M at 2026-03-31 — the company is self-funding the launch, with no financing overhang disclosed into the PDUFA.
• Targets repriced above spot. Piper Sandler Overweight, PT raised to $165 from $88 (2026-07-30); HC Wainwright Buy, PT $165 (2026-07-30); Canaccord Genuity Buy, PT $161 (2026-07-30, after a $150 mark on 2026-07-29).

Bear Case

• A four-month catalyst vacuum. Between the 2026-07-29 print and the 2026-12-17 PDUFA there is no company-confirmed binary. BELLA Part A, the ROSELLA EU MAA decision and the MONARCH Phase 2b MASH readout are all guided only to "end of 2026".
• Dispersion is extreme and one side is loud. Wolfe Research downgraded to Underperform with a $50 price target on 2026-07-27, two days before the beat. The spread from $50 to $165 is a 3.3x range on the same asset; the consensus 12-month target across five brokerages is quoted at $134.50 (MarketBeat, August 2026).
• The move is large and recent. 3-month return +111.9% into the 2026-08-07 close of $110.77. A gap-up of that size leaves no intervening structure between the pre-print shelf near $92 and current levels.
• Insider supply into strength. Joseph Douglas Lyon sold 1,540 shares at an average $114.16 on 2026-08-03, a 21.89% reduction of the reported holding, after 5,000 shares at $65.00 on 2026-05-27. A Form 144 proposed sale was filed 2026-07-07 near the prior highs.
• Litigation is unresolved. A securities class action and an amended former-employee complaint (2026-06-03) remain live and produce headline risk that clusters on strength.
• The Cushing's file already failed once. The original NDA drew a Complete Response Letter; the December decision is a re-run of a review that has previously gone against the company.

Setup & Price Structure

• Last completed daily close $110.77 (2026-08-07); 52-week high $118.32, so 6.4% below it; RSI(14) 64.8 — elevated but not at the extreme the July note flagged.
• The defining structure is the 2026-07-30 gap. Shares traded near $92 through mid-July; the +21.95% after-hours reaction on 2026-07-29 opened a window that has not been revisited. That $92 shelf is the first level with real prior trade beneath it.
• Life-cycle: ACCELERATING. The dating is specific — a beat-and-raise on 2026-07-29, three price-target increases to $150–$165 on 2026-07-30, a first-ever Lifyorli revenue line, and a new 52-week high established after the print. This is the second acceleration leg of 2026, following the 2026-05-29 ASCO overall-survival release.
• Crowding observables, stated without a verdict: institutional and hedge-fund ownership reported at 93.61%; retail-facing coverage clustered on 2026-07-30 across at least four Benzinga items; insider selling at $114.16 within four sessions of the high; spot now sits below all three post-print targets, inverting the July condition when price traded above the $88.83 consensus.
• What would date a flip to MATURING: several weeks of failure to exceed $118.32 while coverage volume stays high, or a Q3 print showing Lifyorli sequential growth stalling near the $47.6M base.

Catalyst Calendar (next 30 days)

• No company-confirmed binary falls between 2026-08-08 and 2026-09-07. The 10-Q for Q2 followed the 2026-07-29 release; guidance has just been reset.
• ~2026-09-15 (est.) — ESMO Congress 2026 abstract titles typically publish in mid-September; any relacorilant ovarian-cancer abstract would be the first new clinical datapoint since ASCO on 2026-05-29. Unconfirmed.
• ~2026-11-04 (est.) — Q3 2026 print. The observable is whether Lifyorli exceeds $47.6M sequentially and whether the $1.1–1.2B FY guide is raised a third time or trimmed.
• 2026-12-17 — PDUFA target action date, relacorilant for hypercortisolism. The single largest dated re-rating lever.
• ~2026-12-31 (est.) — BELLA Part A topline, ROSELLA EU MAA decision, MONARCH Phase 2b MASH readout, all guided to "end of 2026" on the Q2 call.

What Would Change Our Mind

The gap created on 2026-07-30 is the whole structure; nothing else has been built since. Losing it removes the evidence that the launch quarter changed the equity's range, and the gradeable version of that is a weekly close below $92 — the shelf where shares traded before the print. A secondary confirmation would be the 2026-12-17 PDUFA passing without an approval, since the Cushing's indication carries the second-product optionality that the current multiple embeds and this file has already drawn one Complete Response Letter. On the fundamental side, the number to watch is Lifyorli's sequential line: a Q3 print near or below $47.6M, or any trim to the $1.1–1.2B FY guide, would say the 1,300-patient start figure was front-loaded trialling rather than durable adoption. A move above $118.32 on continued volume, by contrast, would extend the accelerating read rather than resolve it.

Correlation Notes

• The name trades on its own calendar. The dated moves of 2026 — 2026-03-25 approval, 2026-05-29 ROSELLA overall-survival data (+15.4%), 2026-06-17 resubmission, 2026-07-29 print (+21.95% after hours) — are all company-specific. On 2026-07-30 the broad tape's driver was Microsoft's 43% cloud growth reviving semis; the biotech move that day was unrelated to it.
• Sector beta still applies through XBI/IBB flows, and the 2026-07-30 session also carried a 19-year high in 30-year yields. A profitable, cash-generative biotech with $544.6M on the balance sheet at 2026-06-30 is less exposed to that channel than pre-revenue peers, but not insulated from it.
• There is no clean listed comparable for selective cortisol modulation; correlation to other Cushing's-adjacent names is event-driven rather than persistent, so read-through from peer FDA outcomes should be treated as weak evidence.